{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:49:01Z","timestamp":1794278941109,"version":"4.9.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R24 AI118629"],"award-info":[{"award-number":["R24 AI118629"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK094738"],"award-info":[{"award-number":["R01 DK094738"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK132050"],"award-info":[{"award-number":["R01 DK132050"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01 DK136523"],"award-info":[{"award-number":["U01 DK136523"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["JTC 185572"],"award-info":[{"award-number":["JTC 185572"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 168954"],"award-info":[{"award-number":["PJT 168954"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1053\/j.gastro.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:25:49Z","timestamp":1708489549000},"page":"409-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":291,"title":["AGA Clinical Practice Guideline on Fecal Microbiota\u2013Based Therapies for Select Gastrointestinal Diseases"],"prefix":"10.1053","volume":"166","author":[{"given":"Anne F.","family":"Peery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron P.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Imdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Altayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.01.008_bib1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.gastro.2023.05.032","article-title":"Gut microbiome composition is associated with future onset of Crohn's disease in healthy first-degree relatives","volume":"165","author":"Raygoza Garay","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2024.01.008_bib3","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.01.008_bib4","first-page":"CD013871","article-title":"Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2024.01.008_bib5","first-page":"CD012774","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"4","author":"Imdad","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2024.01.008_bib7","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.01.008_bib8","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.01.008_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1053\/j.gastro.2024.01.008_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2024.01.008_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"key":"10.1053\/j.gastro.2024.01.008_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.01.008_bib13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"CMAJ"},{"key":"10.1053\/j.gastro.2024.01.008_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1053\/j.gastro.2024.01.008_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076269","article-title":"Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C.\u00a0difficile infection with oral vancomycin or metronidazole","volume":"8","author":"Abujamel","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.01.008_bib17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1136\/gutjnl-2019-319548","article-title":"International consensus conference on stool banking for faecal microbiota transplantation in clinical practice","volume":"68","author":"Cammarota","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.01.008_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.chom.2020.01.018","article-title":"Regulatory Considerations for fecal microbiota transplantation products","volume":"27","author":"Carlson","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2024.01.008_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/apt.13144","article-title":"Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs vancomycin for the treatment of recurrent Clostridium difficile infection","volume":"41","author":"Cammarota","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciw731","article-title":"Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial","volume":"64","author":"Hota","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/M16-0271","article-title":"Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial","volume":"165","author":"Kelly","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/apt.16309","article-title":"Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections","volume":"53","author":"Rode","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib25","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2024.01.008_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/ciy259","article-title":"Results from a randomized, placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection","volume":"67","author":"Dubberke","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","article-title":"Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Baunwall","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib28","first-page":"S63","article-title":"S144 CP101 Engraftment drives efficacy: results from a randomized, placebo-controlled trial evaluating CP101, an investigational orally administered microbiome therapeutic for prevention of recurrent C.\u00a0difficile Infection","volume":"116","author":"Allegretti","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib29","first-page":"S63","article-title":"S145 Week 24 efficacy and safety data from PRISM3: a randomized, placebo-controlled trial evaluating CP101, an investigational orally administered microbiome therapeutic for the prevention of recurrent C.\u00a0difficile infection","volume":"116","author":"Allegretti","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40121-022-00744-3","article-title":"Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection","volume":"12","author":"Dubberke","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib31","first-page":"9","article-title":"522. Significant improvement in health-related quality of life (HRQL) with RBX2660: results from a phase 3 randomized, placebo-controlled trial in recurrent Clostridioides difficile infection (PUNCH CD3)","author":"Feuerstadt","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53570","article-title":"Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial","volume":"6","author":"Garey","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1053\/j.gastro.2024.01.008_bib33","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.14309\/01.ajg.0000772996.83378.7c","article-title":"S131 CP101, an investigational orally administered microbiome therapeutic, increases intestinal microbiome diversity and prevents recurrent C.\u00a0difficile infection: results from a randomized, placebo-controlled trial","volume":"116","author":"Khanna","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib35","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1093\/cid\/ciac554","article-title":"Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a Phase 3 randomized trial","volume":"76","author":"Lapin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib36","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib37","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.01.008_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG Clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2024.01.008_bib39","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2024.01.008_bib40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2024.01.008_bib41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jhin.2018.07.037","article-title":"The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines","volume":"100","author":"Mullish","year":"2018","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1053\/j.gastro.2024.01.008_bib44","first-page":"6498","article-title":"Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients","volume":"12","author":"Ali","year":"2021","journal-title":"J\u00a0Cancer"},{"key":"10.1053\/j.gastro.2024.01.008_bib45","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.mayocp.2017.08.016","article-title":"Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: a single-institution retrospective case series","volume":"92","author":"Hefazi","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.gastro.2024.01.008_bib46","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s10620-021-07024-z","article-title":"Fecal microbiota transplantation is safe for clostridiodies difficile infection in patients with solid tumors undergoing chemotherapy","volume":"67","author":"Mendelsohn","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.01.008_bib47","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/tid.12550","article-title":"Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients","volume":"18","author":"Webb","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib48","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1053\/j.gastro.2020.07.045","article-title":"Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile Infection","volume":"159","author":"Allegretti","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cgh.2016.11.028","article-title":"Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience","volume":"15","author":"Chin","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib50","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1097\/MIB.0000000000000908","article-title":"Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease","volume":"22","author":"Fischer","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ajt.15058","article-title":"Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience","volume":"19","author":"Cheng","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1053\/j.gastro.2024.01.008_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12967","article-title":"Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature","volume":"20","author":"Lin","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10620-020-06198-2","article-title":"Risk factors that predict the failure of multiple fecal microbiota transplantations for Clostridioides difficile Infection","volume":"66","author":"Allegretti","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.01.008_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/gr1436","article-title":"Fecal microbiota transplantation in patients with recurrent Clostridium difficile infection: a four-year single-center retrospective review","volume":"14","author":"Ashraf","year":"2021","journal-title":"Gastroenterology Res"},{"key":"10.1053\/j.gastro.2024.01.008_bib55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ajg.2016.180","article-title":"Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study","volume":"111","author":"Fischer","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib56","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3748\/wjg.v24.i47.5403","article-title":"Five years of fecal microbiota transplantation - an update of the Israeli experience","volume":"24","author":"Greenberg","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ibd\/izy398","article-title":"Microbial engraftment and efficacy of fecal microbiota transplant for Clostridium difficile in patients with and without inflammatory bowel disease","volume":"25","author":"Hirten","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib58","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.cgh.2016.02.018","article-title":"Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection","volume":"14","author":"Khoruts","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jgh3.12093","article-title":"Fecal microbiota transplantation in recurrent Clostridium difficile infection: a retrospective single-center chart review","volume":"3","author":"Kim","year":"2019","journal-title":"JGH Open"},{"key":"10.1053\/j.gastro.2024.01.008_bib60","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s10620-020-06147-z","article-title":"Fecal microbiota transplantation for Clostridioides difficile in high-risk older adults is associated with early recurrence","volume":"65","author":"Luo","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.01.008_bib61","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00384-015-2396-2","article-title":"Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile","volume":"31","author":"Mandalia","year":"2016","journal-title":"Int J Colorectal Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib62","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1007\/s10620-017-4580-4","article-title":"Outcomes of fecal microbiota transplantation for Clostridium difficile infection in patients with inflammatory bowel disease","volume":"62","author":"Meighani","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.01.008_bib63","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/tid.12726","article-title":"Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised patients: a single-center experience","volume":"19","author":"Alrabaa","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.15403\/jgld-3800","article-title":"Fecal microbiome transplantation for recurrent Clostridioides difficile infection: treatment efficacy, short and long-term follow-up results from consecutive case series","volume":"30","author":"Urbonas","year":"2021","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib65","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhin.2020.09.027","article-title":"Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre","volume":"106","author":"Navalkele","year":"2020","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1053\/j.gastro.2024.01.008_bib66","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1007\/s10620-021-07347-x","article-title":"Fecal microbiota transplant for Clostridioides difficile infection is safe and efficacious in an immunocompromised cohort","volume":"67","author":"Suchman","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.01.008_bib67","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ajg.2014.133","article-title":"Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients","volume":"109","author":"Kelly","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib68","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/MEG.0000000000002159","article-title":"Earlier use of fecal transplant administration during hospitalization for Clostridioides difficile infection may improve outcome","volume":"33","author":"Dhere","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib69","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jclinepi.2005.04.003","article-title":"Case reports and case series from Lancet had significant impact on medical literature","volume":"58","author":"Albrecht","year":"2005","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2024.01.008_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/trf.14387","article-title":"A\u00a0systematic review of incentives in blood donation","volume":"58","author":"Chell","year":"2018","journal-title":"Transfusion"},{"key":"10.1053\/j.gastro.2024.01.008_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tmrv.2021.08.007","article-title":"Blood donation and monetary incentives: a meta-analysis of cost-effectiveness","volume":"36","author":"Bruers","year":"2022","journal-title":"Transfus Med Rev"},{"key":"10.1053\/j.gastro.2024.01.008_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12889-019-6948-1","article-title":"Prevalence of hepatitis G virus infection among 67,348 blood donors in mainland China","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1053\/j.gastro.2024.01.008_bib76","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E.\u00a0coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MCG.0000000000000968","article-title":"The impact of Clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"53","author":"Tariq","year":"2019","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2007.128231","article-title":"Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease","volume":"57","author":"Ananthakrishnan","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.01.008_bib79","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/ibd\/izaa283","article-title":"Inflammatory bowel disease outcomes following fecal microbiota transplantation for recurrent C.\u00a0difficile infection","volume":"27","author":"Allegretti","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib80","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/apt.13290","article-title":"Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate","volume":"42","author":"Fischer","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/apt.14816","article-title":"Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions","volume":"48","author":"Ianiro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib82","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MCG.0b013e31829004ae","article-title":"Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation","volume":"47","author":"Weingarden","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib83","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cgh.2019.12.029","article-title":"Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection","volume":"18","author":"Cheng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cid\/cix762","article-title":"Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections","volume":"66","author":"Hocquart","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib85","first-page":"500","article-title":"Fecal microbiota transplantation may reduce the mortality of patients with severe and fulminant Clostridioides difficile infection compared to standard-of-care antibiotics in a community hospital","volume":"23","author":"Mironova","year":"2022","journal-title":"J\u00a0Dig Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib86","article-title":"Fecal microbiota transplantation for fulminant Clostridioides difficile infection: a combined medical and surgical case series","volume":"15","author":"Spartz","year":"2023","journal-title":"Cureus"},{"key":"10.1053\/j.gastro.2024.01.008_bib87","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/apt.15526","article-title":"Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients","volume":"50","author":"Tixier","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib88","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmi.2018.12.007","article-title":"Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study","volume":"25","author":"Gentry","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2024.01.008_bib89","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijantimicag.2013.08.013","article-title":"Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection","volume":"42","author":"Lam","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/j.gastro.2024.01.008_bib90","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/bjs.8868","article-title":"Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis","volume":"99","author":"Bhangu","year":"2012","journal-title":"Br J Surg"},{"key":"10.1053\/j.gastro.2024.01.008_bib91","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib92","first-page":"2753","article-title":"Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis-results of a randomized controlled trial","volume":"10","author":"Brezina","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib93","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.01.008_bib94","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12876-021-01856-9","article-title":"Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study","volume":"21","author":"Crothers","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12934-021-01513-6","article-title":"Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study","volume":"20","author":"Fang","year":"2021","journal-title":"Microb Cell Fact"},{"key":"10.1053\/j.gastro.2024.01.008_bib96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib97","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib98","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.01.008_bib99","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","article-title":"Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis","volume":"149","author":"Rossen","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ecco-jcc\/jjab165","article-title":"Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: the CRAFT UC randomised controlled trial","volume":"16","author":"Sarbagili Shabat","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.01.008_bib101","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ecco-jcc\/jjz060","article-title":"Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study","volume":"13","author":"Sood","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.01.008_bib102","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib103","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2023.03.019","article-title":"Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection","volume":"31","author":"Yadegar","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2024.01.008_bib104","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","article-title":"Key determinants of success in fecal microbiota transplantation: from microbiome to clinic","volume":"31","author":"Porcari","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2024.01.008_bib105","article-title":"Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics","volume":"3","author":"Podlesny","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib106","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41591-022-01913-0","article-title":"Drivers and determinants of strain dynamics following fecal microbiota transplantation","volume":"28","author":"Schmidt","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.01.008_bib107","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.01.008_bib108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"10.1053\/j.gastro.2024.01.008_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000497042","article-title":"Combined endoscopic and oral fecal microbiota transplantation in patients with antibiotic-dependent pouchitis: low clinical efficacy due to low donor microbial engraftment","volume":"4","author":"Herfarth","year":"2019","journal-title":"Inflamm Intest Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib111","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/ibd\/izab001","article-title":"Fecal microbiota transplantation in chronic pouchitis: a randomized, parallel, double-blinded clinical trial","volume":"27","author":"Karjalainen","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib112","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S2468-1253(21)00101-1","article-title":"Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium","volume":"6","author":"Shen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","article-title":"AGA Clinical practice guideline on the management of pouchitis and inflammatory pouch disorders","volume":"166","author":"Barnes","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib114","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.gastha.2023.04.005","article-title":"Safety and efficacy of fecal microbiota transplant in chronic pouchitis\u2014a systematic review with meta-analysis","volume":"2","author":"Kahan","year":"2023","journal-title":"Gastro Hep Advances"},{"key":"10.1053\/j.gastro.2024.01.008_bib115","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/apt.16328","article-title":"An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials","volume":"53","author":"Sedano","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib116","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.cgh.2018.09.042","article-title":"Identifying outcomes in clinical trials of pouchitis for the development of a core outcome set","volume":"17","author":"Ma","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib117","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2468-1253(19)30198-0","article-title":"Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial","volume":"4","author":"Aroniadis","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib118","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","article-title":"Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study","volume":"69","author":"El-Salhy","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.01.008_bib119","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12934-021-01720-1","article-title":"The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors","volume":"20","author":"Lin","year":"2021","journal-title":"Microb Cell Fact"},{"key":"10.1053\/j.gastro.2024.01.008_bib120","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1080\/21655979.2021.1999374","article-title":"Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules","volume":"12","author":"Guo","year":"2021","journal-title":"Bioengineered"},{"key":"10.1053\/j.gastro.2024.01.008_bib121","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","article-title":"Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study","volume":"67","author":"Halkjaer","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.01.008_bib122","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/00365521.2021.1915375","article-title":"The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study","volume":"56","author":"Madsen","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib123","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000034","article-title":"The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study","volume":"10","author":"Holster","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2020.07.013","article-title":"Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial","volume":"160","author":"Holvoet","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.01.008_bib126","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/apt.15740","article-title":"Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome","volume":"51","author":"Lahtinen","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.01.008_bib127","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/microorganisms10091819","article-title":"The effect of anaerobically cultivated human intestinal microbiota compared to fecal microbiota transplantation on gut microbiota profile and symptoms of irritable bowel syndrome, a double-blind placebo-controlled study","volume":"10","author":"Mazzawi","year":"2022","journal-title":"Microorganisms"},{"key":"10.1053\/j.gastro.2024.01.008_bib128","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.2020067","article-title":"Effect of antibiotic pretreatment on bacterial engraftment after fecal microbiota transplant (FMT) in IBS-D","volume":"14","author":"Singh","year":"2022","journal-title":"Gut Microbes"},{"key":"10.1053\/j.gastro.2024.01.008_bib129","article-title":"Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: a randomized, clinical trial","volume":"9","author":"Tkach","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.gastro.2024.01.008_bib130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.01.008_bib131","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG CLINICAL GUIDELINe: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.01.008_bib132","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dld.2022.11.015","volume":"55","author":"Barbara","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2024.01.008_bib133","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:54:18Z","timestamp":1762163658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0016508524000416"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.01.008","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Guideline on Fecal Microbiota\u2013Based Therapies for Select Gastrointestinal Diseases","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}